Introduction: Korea’s Most Trusted Pharmaceutical Company
When international investors think of Korean stocks, names like Samsung, Hyundai, and SK Hynix typically come to mind. But beneath the surface of Korea’s tech-dominated market lies a pharmaceutical powerhouse with a century-long legacy, groundbreaking drug development partnerships, and a reputation that consistently ranks it among the most admired companies in the country. Meet Yuhan Corporation (유한양행, 000100.KS) — a company that every global investor interested in Asian healthcare should have on their radar.
Founded in 1926 by Dr. Ilhan New (유일한), a Korean-American entrepreneur and independence activist, Yuhan Corporation was established with a mission that still defines its identity: to improve public health and contribute to society. Nearly a hundred years later, the company has evolved from a domestic pharmaceutical manufacturer into a biotech-forward enterprise with licensing deals that have attracted the attention of some of the world’s largest drug makers.
Business Overview: More Than Just a Legacy Brand
Yuhan Corporation operates across several key business segments, making it a diversified play within the Korean healthcare and consumer goods landscape:
- Pharmaceuticals: The core of Yuhan Corporation’s business, this segment includes prescription drugs, over-the-counter medicines, and a growing pipeline of novel therapeutics. The company has long been one of Korea’s top-selling pharmaceutical firms, with strong positions in liver disease treatments, metabolic disorders, antibiotics, and respiratory care.
- New Drug Development & Licensing: In recent years, Yuhan Corporation has aggressively invested in R&D and established itself as a credible player in the global drug development arena. Its subsidiary, Yuhan USA, and strategic partnerships with multinational pharma giants have positioned it as a bridge between Korean biotech innovation and global commercialization.
- Consumer Healthcare & Chemicals: Through subsidiaries and affiliates, the company also has exposure to consumer health products, industrial chemicals, and other diversified businesses, providing a stable revenue base that supports its higher-risk pharmaceutical R&D efforts.
What sets Yuhan Corporation apart from many Korean pharma peers is its corporate governance and reputation. The company is widely regarded as one of the most ethically managed firms in Korea, consistently topping surveys on corporate trust and social responsibility — a legacy of its founder’s philosophy of putting public welfare above profit.
The Landmark Lazertinib Deal and Global Ambitions
If there is a single reason why Yuhan Corporation has captured the attention of the global investment community, it is Lazertinib — a third-generation EGFR tyrosine kinase inhibitor developed for non-small cell lung cancer (NSCLC). This drug has become one of the most significant outbound licensing deals in Korean pharmaceutical history.
In 2018, Yuhan Corporation signed a landmark licensing agreement with Janssen Biotech, the pharmaceutical arm of Johnson & Johnson, granting global development and commercialization rights for Lazertinib. The deal was valued at up to $1.25 billion, including upfront payments, milestones, and royalties — a staggering figure for a Korean pharma company and a powerful validation of its R&D capabilities.
Lazertinib has since advanced through clinical trials as both a monotherapy and in combination with amivantamab (Janssen’s bispecific antibody). The combination therapy, branded as part of the MARIPOSA clinical trial program, has shown highly promising results in first-line treatment of EGFR-mutated NSCLC. In 2024, the U.S. FDA approved the combination of amivantamab and Lazertinib (marketed under the brand name Lazcluze) for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations. This regulatory milestone marked a historic moment — not just for Yuhan Corporation, but for the entire Korean pharmaceutical industry.
For international investors, the Lazertinib story is critical because it represents a recurring revenue stream through milestone payments and royalties from one of the world’s largest pharmaceutical companies. It also signals that Yuhan Corporation’s R&D pipeline is capable of producing globally competitive therapeutics, raising the probability of future high-value deals.
Recent Financial Performance and Market Position
Yuhan Corporation’s financial performance reflects its dual identity as both a stable domestic pharma company and an emerging global biotech player. In recent fiscal years, the company has delivered steady revenue growth driven by its established pharmaceutical portfolio, while periodic milestone payments from the Janssen deal have provided significant boosts to its bottom line.
Key financial highlights for investors to consider include:
- Revenue Stability: Yuhan Corporation generates consistent top-line revenue from its domestic pharmaceutical sales, which include well-known brands in liver care, metabolic treatments, and respiratory medicines. This provides a defensive quality that many pure-play biotech firms lack.
- R&D Investment: The company has steadily increased its R&D spending as a percentage of revenue, reflecting its strategic pivot toward novel drug development. Its pipeline includes candidates in oncology, metabolic diseases, and respiratory conditions at various stages of preclinical and clinical development.
- Balance Sheet Strength: Yuhan Corporation maintains a relatively healthy balance sheet with manageable debt levels and sufficient cash reserves to fund its R&D ambitions without excessive dilution or financial strain.
- Market Capitalization: Listed on the Korea Exchange (KRX) under ticker 000100.KS, Yuhan Corporation is one of the larger pharmaceutical companies in Korea by market capitalization, providing reasonable liquidity for institutional investors.
The stock has experienced periods of significant volatility, often driven by clinical trial data readouts and regulatory decisions related to Lazertinib. For investors with a longer time horizon, these fluctuations may present opportunities to build positions in a company with genuine global pharmaceutical potential.
Why International Investors Should Pay Attention
There are several compelling reasons why Yuhan Corporation deserves a place on the watchlists of international investors looking for exposure to Asian healthcare:
- Proven Global Deal-Making: The Janssen/J&J partnership is not a speculative hope — it is a validated, revenue-generating relationship with one of the world’s premier pharmaceutical companies. The FDA approval of Lazertinib in combination therapy adds a layer of de-risking that few Korean biotech stories can match.
- Deep Pipeline Potential: Beyond Lazertinib, Yuhan Corporation is building a diversified pipeline that could yield additional licensing deals or proprietary product launches in the coming years.
- ESG and Governance Appeal: In an era where environmental, social, and governance (ESG) factors increasingly drive investment decisions, Yuhan Corporation’s century-long reputation for ethical management and social contribution is a meaningful differentiator.
- Korean Pharma Sector Tailwinds: South Korea’s government has designated biotechnology and pharmaceuticals as strategic growth industries, providing regulatory support, tax incentives, and funding programs that benefit companies like Yuhan Corporation.
- Valuation Considerations: Compared to U.S.-listed biotech firms with similar pipeline profiles and partnership deals, Korean pharmaceutical companies often trade at lower multiples, potentially offering international investors a more attractive entry point.
Conclusion
Yuhan Corporation represents a rare combination in the world of pharmaceutical investing: a nearly century-old company with deep domestic roots, an impeccable corporate reputation, and a genuinely exciting global drug development story. The successful advancement and FDA approval of Lazertinib in partnership with Johnson & Johnson’s Janssen has elevated Yuhan Corporation from a respected Korean pharma name to a company with legitimate global relevance.
For international investors seeking diversified exposure to the Asian healthcare sector — beyond the usual mega-cap tech names — Yuhan Corporation offers a compelling narrative of innovation, stability, and growth potential. As the company continues to advance its pipeline and collect on the value of its global partnerships, it may increasingly